Rapid, accurate and sensitive ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) methods were developed and validated for the simultaneous quantitation of amoxicillin and clavulanic acid in human plasma and urine samples. Amoxicillin and clavulanic acid in both plasma and urine were extracted using a solid-phase extraction method. The compounds were separated on an Acquity UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm). Ampicillin was used as the internal standard (IS) in plasma, while amoxicillin-d4 and sulbactam were used as ISs in urine. The lower limit of quantitation was 0.0500 and 0.0250 μg/mL for amoxicillin and clavulanic acid in plasma, and 0.0500 μg/mL for both analytes in urine. The established methods were validated in terms of selectivity, precision, accuracy, linearity, matrix effect, recovery, carryover, interaction, dilution integrity and stability, and successfully applied to a pharmacokinetic study of amoxicillin sodium and clavulanate potassium (10:1) injection in healthy volunteers.
Introduction
The combination of amoxicillin (Fig. 1A ) and clavulanic acid (Fig. 1B) is clinically used for various infections, such as lower respiratory tract infections caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis; 1 urinary tract and skin infections due to Escherichia coli and Staphylococcus aureus. [2] [3] [4] Clavulanic acid, produced by Streptomyces clavuligerus, is an inhibitor of β-lactamases, providing a protection effect on hydrolysis of amoxicillin by β-lactamases; it also provides synergistic antibacterial effect. 5 A series of combination ratios (2:1, 4:1, 7:1, or 8:1) are commercially available. Increasing antibiotics resistance leads to less clinical efficacy, 6, 7 which needs optimization of the dose regimen in the clinical treatment of old and new antibiotics. 8 Increasing proportion of amoxicillin in the combination can achieve a better bactericidal effect, especially for Penicillinresistant streptococcus pneumoniae (PRSP). 9, 10 While the combination of clavulanic acid seems to be associated with a higher risk of hepatotoxicity than amoxicillin alone, 11, 12 a new combination of amoxicillin and clavulanic acid at a ratio 10:1 was developed to improve the clinical efficacy and safety.
In general, clinical efficacy is closely associated with the antibiotic concentrations achieved in the infection site, typically in blood and urine. 13 The concentrations of antibiotics should be comparable to minimal inhibition concentration (MIC) in the blood, urine and infection site during the treatment. 14, 15 Furthermore, a pharmacokinetic/pharmacodynamic (PK/PD) study indicated that the amoxicillin and clavulanic acid combination for Streptococcus pneumoniae, Haemophilus influenzae was effective when the percentage time above the minimal inhibition concentration (%T>MIC) of the plasma concentration was over 35 -40%. 9, 10 So it is important to develop a sensitive and reliable detection method to assess drug pharmacokinetics in human, and then to find an appropriate dose regimen in the clinical.
We established reliable determination methods for quantification of two compounds in plasma and urine to subsequently obtain pharmacokinetic profiles of this combination in Chinese healthy volunteers.
Generally, the larger the concentration difference between amoxicillin and clavulanic acid is, the more difficult the determination methods become. For example, there is the saturation of a high-concentration compound and the problem of sensitivity with a low-concentration compound. The reported methods were developed according to different purposes of each study, but no one can meet the requirement of PK samples determination under the circumstances. Yoon et al. reported a method to detect amoxicillin and clavulanic acid in plasma samples; it had a lower limit of quantitation (LLOQ) of 0.125 and 0.0625 μg/mL for amoxicillin and clavulanic acid in plasma. 16 The sensitivity of the method may impact on accurate calculation of the terminal elimination PK parameters. Zhang et al. reported the plasma concentration determination methods for amoxicillin and clavulanic acid in two separated methods. 17 In addition, no LC-MS/MS method was reported for the simultaneous determination of amoxicillin and clavulanic acid in urine samples. Also, there are other problems such as high matrix effect in urine samples, 18 poor stability of clavulanic acid at room temperature and after freeze-thaw circle, 19, 20 poor stability of clavulanic acid in long-term stability tests. 21 Therefore, it is necessary to develop sensitive, reliable methods to simultaneously determine amoxicillin and clavulanic acid in both plasma and urine samples to assess pharmacokinetics characteristics of combination of two compounds at a ratio of 10:1 in humans.
In this study, we developed the UPLC-MS/MS methods for assay of amoxicillin and clavulanic acid in plasma and urine samples. Both methods were validated to meet criteria of quantitative analysis of biological samples requirements. The methods were then successfully applied to a pharmacokinetic study after the infusion of amoxicillin sodium and clavulanate potassium (10:1) in healthy Chinese volunteers. The methods also has potential utility for other PK studies.
Experimental

Reagents and materials
Amoxicillin (purity 85.8%), clavulanic acid (purity 95.0%), ampicillin (internal standard 1: IS1, purity 86.5%, Fig. 1C ) and sulbactam (IS3, purity 90.6%, Fig. 1E ) reference standards were purchased from National Institute for the Control of Pharmaceutical and Biological Products of China (Beijing, China). Amoxicillin-d4 (IS2, purity 98.1%, isotopic purity 98.6%, Fig. 1D ) was purchased from TLC PharmaChem Inc. (Vaughan, Canada). Acetonitrile, methanol and formic acid (HPLC grade) were produced by Sigma-Aldrich Laborchemikalien GmbH (St. Louis, MO, USA). Phosphoric acid (GR grade) was produced by Ling-feng Chemical Reagent Co., Ltd. (Shanghai, China). The ultrapure water was freshly prepared in a Milli-Q lab system (Millipore, USA). The Oasis ® HLB 96-well plate and column (30 mg/1 mL) were produced by Waters Company Inc. (Milford, MA, USA). Drug-free human plasma (heparin lithium as anticoagulant) and urine were obtained from healthy volunteers.
Instrumentation
The UPLC-MS/MS system comprises a Waters Acquity ultraperformance liquid chromatography (Milford, MA, USA) and an API 4000 QTRAP triple quadrupole mass spectrometer equipped with an electrospray ionization (ESI) probe (AB SCIEX, MA, USA). Data acquisition and processing were performed using Analyst 1.6 software (AB SCIEX).
UPLC-MS/MS conditions
Chromatographic separation was carried out on an Acquity UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm, Waters) with the column temperature at 50 C. The samples on the column were eluted with a gradient mixture of acetonitrile with 0.2% formic acid (solvent A) and 0.2% aqueous formic acid solution (solvent B) for the assay of amoxicillin and clavulanic acid in plasma, acetonitrile (solvent A) and 0.5% aqueous formic acid solution (solvent B) for urine samples in gradient elution (Table 1 ) at a flow rate of 0.6 mL/min, and with an extra 0.3 mL/min acetonitrile perfusion after column from another UPLC pump for urine sample detection. The injection volume was 5 μL and the autosampler temperature was maintained at 4 C for both the plasma and urine samples. The total run time was 2.4 min in plasma and 2.8 min in urine, respectively.
Both analytes and IS were determined by electrospray ionization (ESI) in the negative ion mode. Quantification was performed in the multiple reaction monitoring (MRM) mode at an ion transition of m/z 363.9 → 223.4 for amoxicillin, The transition and collision energy of amoxicillin in urine was the same as the plasma. The curtain gas, ion source gas 1 and 2 were set at 25 arb, 55 psi and 55 psi, respectively. The collisionally activated dissociation was set as medium. The temperature and capillary voltages were set at 450 C and -4500 V.
Preparation of the stock solution, standards and quality control samples
The stock solutions of amoxicillin, clavulanic acid and ISs were all prepared in ultrapure water at a concentration of 1000 μg/mL and stored at -70 C. The working solution was prepared by dilution of the stock solution in ultrapure water to obtain the expected concentrations. Drug-free plasma or urine samples were spiked with a working solution to obtain the calibration standard and quality-control (QC) samples.
The nominal concentrations of calibration standards (amoxicillin/clavulanic acid) were 0.0500/0.0250, 0.100/0.0500, 0.500/0.250, 1.00/0.500, 2.00/1.00, 5.00/2.50, 10.0/5.00 μg/mL in plasma and 0.0500/0.0500, 0.100/0.100, 0.500/0.500, 1.00/1.00, 2.00/2.00, 5.00/5.00, 10.0/10.0 μg/mL in urine, respectively. The nominal concentrations of QC samples (amoxicillin/clavulanic acid) were 0.0500/0.0250, 0.150/0.0750, 1.60/0.800 and 8.00/4.00 μg/mL in plasma and 0.0500/0.0500, 0.150/0.150, 1.60/1.60 and 8.00/8.00 μg/mL in urine, respectively.
The IS1 was prepared by diluting the ampicillin stock soulution to a concentration of 2.00 μg/mL with ultrapure water. The stock solution of IS2/IS3 was diluted with ultrapure water to prepare the working solution of the internal standard (containing 10.0/1.00 μg/mL of IS2/IS3).
Sample preparation
The same extraction method was used for plasma and urine samples. Initially, an aliquot of 200 μL plasma or urine sample was placed in a tube, 20 μL of IS1 or IS2/IS3 solution and 200 μL 4% phosphoric acid solution were added and vortexed for 10 s. The samples were then loaded on a Oasis ® HLB 96-well plate or column preconditioned with 1 mL of methanol followed by 1 mL of ultrapure water, and washed with 1 mL of a 0.01% aqueous formic acid solution and 1 mL of methanol-0.1% aqueous fomic acid solution (2/98, v/v) to remove any impurities. The desired analytes were eluted twice with 300 μL 20% acetonitrile, and collected into a 96-well polypropylene collection plate. After vortexing the plate for 30 s, 5 μL eluent was injected into the UPLC-MS/MS system.
Method validation
The UPLC-MS/MS methods for quantitation were validated with reference to the FDA Guidance for the Industry: Bioanalytical Method Validation 22 and European Medicines Agency (EMA) guideline on bioanalytical method validation. 23 The selectivity was tested by using the blank plasma or urine from six sources to evaluate the potential interference from endogenous components in matrices at the retention times of amoxicillin, clavulanic acid and IS. Additionally, the impact of hemolysis (containing 2% whole blood) and lipidemia on the assay performance were examined. The results were compared with those obtained from an aqueous solution of the analytes at a concentration near to the lower limit of quantitation (LLOQ). Cross-interference was assessed by observing the interference signal in other ions channel after injecting a high QC sample containing each analyte.
The linearity of the assay was examined by plotting the peakarea ratio of amoxicillin or clavulanic acid to IS against the concentration in plasma or urine in duplicates in three batches. The calibration curves of amoxicillin or clavulanic acid were obtained by a 1/x 2 weighted linear regression, respectively. The intra-batch precision and accuracy were assessed by analyzing five replicates of QC samples in one batch. The inter-batch precision was determined by analyzing QC samples in three different batches (at least two days apart). The intra-batch and inter-batch precision and accuracy should not exceed 20% for LLOQ QC samples and 15% for other QC samples.
The extraction recovery of each analyte in plasma or urine was assessed by comparing the peak areas of QC samples with those of the blank matrix extracts spiked with the analytes at four QC concentrations (n = 6). To evaluate the matrix effect, the blank plasma or urine samples from six untreated healthy volunteers, blank hemolysis and lipidemia plasma were extracted. The extracts were spiked with four different concentrations of analytes and IS solution (A).
The corresponding peak-area ratios were then compared with those of analytes in eluent (B). The relative matrix effect factor (MF) was calculated as: MF(%) = A/B × 100%.
Carryover was assessed by injection of blank samples after injection of high QC samples, and this procedure was repeated six times. To evaluate the dilution integrity, the upper limit of quantification (ULOQ) samples of the calibration curves were diluted with blank plasma 1 in 10 or 1 in 20 with six replicates. ULOQ of urine samples were diluted with blank urine at a dilution factor of 10, 100. In order to evaluate other dilution factors such as 1000 and 10000 for urine samples, 859.7/953.8 μg/mL (amoxicillin/clavulanic acid) urine samples were diluted with blank urine as well.
The stability of the stock solution was evaluated at -70 ± 10 C in a freezer by comparison with the freshly prepared solution. Four concentrations of QC samples (n = 3) were put at room temperature for 0, 2, 4 and 6 h to test the short-term stability of amoxicillin and clavulanic acid in plasma, and 0, 2.5, 4.5, 6.5 h in urine at room temperature and 4 C. The QC samples were extracted, loaded onto the autosampler, and kept in the autosampler at 4 C until 12 h and injected at the time points of 0, 2, 4, 6, 8, 10 and 12 h in plasma, and 0, 3, 4, 6, 7, 9 h for urine samples to assess the stability of the extracts in an autosampler. The QC samples were detected after 1, 2 and 3 freeze-thaw cycles to assess the stability by comparing the concentrations of the QC samples prepared initially. The plasma and urine QC samples were stored at -70 ± 10 C for 61 and 26 days, respectively, and then assayed so as to evaluate the longterm stability. Three concentrations of blood QC samples were kept on ice-water at time points of 0, 0.25, 0.5, 0.75 and 1 h, and then centrifuged at 1400g for 10 min at 4 C to assess the whole blood stability during collection and centrifugation procedure. All of the concentrations of QC samples for stability evaluation were calculated using freshly prepared calibration standards.
An incurred sample reanalysis (ISR) was also conducted for the plasma and urine by the computerized random selection of 575 plasma samples (10% of the total study samples) with concentrations near to Cmax or during the elimination phase and 180 urine samples (10% of the total study samples) at different time duration and with different dilution factor. The results were compared with the initial values obtained earlier for the same sample using the same pretreatment procedure. Difference% = 100% ×[(repeat test -initial value)/mean of repeat and initial test results].
Stock solutions of amoxicillin and clavulanic acid and four concentrations of external quality assessment (EQA) samples of plasma were prepared by WuXi AppTec Co., Ltd. Each concentration of the EQA samples were compared with that of QC samples prepared in our lab.
Application of the assay in pharmacokinetic analysis
The validated UPLC-MS/MS methods in this paper were applied to a single-center, random, open, and cross-controlled pharmacokinetic study following a single intravenous infusion of amoxicillin sodium and clavulanate potassium (10:1) in 12 (6 males and 6 females) healthy Chinese subjects. After being stratified by sex, the subjects accepted a single dose intervenous infusion of low, medium or high doses of amoxicillin/clavulanic acid (0. 
Results and Discussion
Method development
The sensitivity of the methods may impact the PK parameters calculation, especially for a low concentration of clavulanic acid in this study. The LLOQ in plasma, reported by Yoon et al., 16 was 2.5-times of that in our UPLC-MS/MS method (0.0500 μg/mL for amoxicillin and 0.0250 μg/mL for clavulanic acid). The given dose in Yoon's study was 0.25/0.125 g (4:1, amoxicillin/clavulanic acid), 16 while it was 0.5/0.05 g (10:1, amoxicillin/clavulanic acid) with lower dose of clavulanic acid in our study. Zhang et al. reported a more sensitive method with LLOQ of 0.005 and 0.05 μg/mL for amoxicillin and clavulanic acid in plasma, 17 but the two analytes were determined by two separate methods, and the running time was 5 -5.5 min, which is time-consuming. Some other LC-MS/MS methods reported for therapeutic drug monitoring were used to determine 11 or 21 antibiotics (containing amoxicillin and clavulanic Fig. 2 Representative chromatograms of amoxicillin (I), clavulanic acid (II) and internal standard 1 (IS1, III) obtained from (a) blank human plasma, (b) blank human plasma spiked with 0.0500 μg/mL of amoxicillin, 0.0250 μg/mL of clavulanic acid and 2.00 μg/mL of IS1 and (c) a volunteer plasma sample at 4 h after intravenous administration of a single dose of 0.5/0.05 g amoxicillin sodium and clavulanate potassium (10:1) (measured concentration was 0.820 μg/mL for amoxicillin and 0.124 μg/mL for clavulanic acid). Fig. 3 Representative chromatograms of amoxicillin (I), clavulanic acid (III), internal standard 2 (IS2, II) and IS3 (IV) obtained from (a) blank human urine, (b) blank human urine spiked with 0.0500 μg/mL of amoxicillin, 0.0500 μg/mL of clavulanic acid, 10.0 μg/mL of IS2 and 1.00 μg/mL of IS3, (c) a volunteer urine sample at 8 -12 h after intravenous administration of a single dose of 0.5/0.05 g amoxicillin sodium and clavulanate potassium (10:1) (measured concentration was 2.41 μg/mL for amoxicillin and 0.0890 μg/mL for clavulanic acid). acid) 18, 24 had much lower sensitivity than in our method. The LLOQ of amoxicillin and clavulanic acid, reported by Carlier et al., was 0.5 μg/mL in plasma. 24 In Cazorla-Reyes's method, it was 0.2 μg/mL for serum samples and 0.5 μg/mL for urine samples. 18 So the reported methods may not be appropriate for our study.
In addition, an UPLC-MS/MS method for simultaneously determination of amoxicillin and clavulanic acid in urine samples was established. The cumulative urine excretion rates of the new combination were about 70.77 and 42.52% for amoxicillin and clavulanic acid in urine.
Besides the generally required validation, whole blood stability, ISR and EQA were also investigated to get reliable determination methods for unstable compound like clavulanic acid.
Two product ions were found as m/z 136. Both amoxicillin and clavulanic acid show high polarity. 25, 26 The solid phases of Acquity BEH C18, Phonomenex Kinetex XB-C18 and Acquity HSS T3 were tested for separation. Also, the HSS T3 column was finally selected because of its 100% compatibility with the aqueous phase, nice peak shape and low baseline noise signal. Mobile phases were also tested, acetonitrile with 0.2% formic acid and 0.2% formic acid was finally chosen for its better chromatographic retention and stronger signal response than others. The running time was 2.4 min for plasma and 2.8 min for urine.
The commonly used pretreatment methods for plasma samples reported in the literature were protein precipitation and liquid-liquid extraction (LLE). 14, 16, 22 While a matrix effect was observed, 16, 22 or not reported 17 in literatures using the above methods. HLB extraction SPE method with high sensitivity and reproducibility but low matrix effect was used in this study. After plasma method was validated, it was attempted to transfer the plasma method to urine. However, strong endogenous interference was found for both analytes and IS. The problem was finally resolved by changing the IS to isotope-labeled analog amoxicillin-d4 for the determination of amoxicillin in urine samples. And as for clavulanic acid, structural analogue of sulbactam was selected as IS. That was why different IS was used in plasma and urine methods. In addition, an extra 0.3 mL/min acetonitrile perfusion after column from another UPLC pump significantly increased the MS signal for the analytes.
Method validation
Typical chromatograms of blank plasma and urine spiked with amoxicillin and clavulanic acid or IS and sample from a subject post-dose are shown in Figs. 2 and 3 . For both the drug and IS, the chromatograms are free from interfering peaks at their retention times.The cross-interference results show that amoxicillin, clavulanic acid and IS had mild (<10.2% for clavulanic acid, <2.1% for amoxicillin and IS) MS signal influence with each other.
The calibration curves show good linearity over the studied concentration range (0.0500 -10.0 μg/mL for amoxicillin and 0.0250 -5.00 μg/mL for clavulanic acid in plasma, 0.0500 -10.0 μg/mL for both analytes in urine), with correlation coefficients (r) > 0.9951. The lowest concentrations in the calibration curves for both amoxicillin and clavulanic acid with signal-to-noise ratio > 5 are used as LLOQs and are determined to be 0.0500 μg/mL for amoxicillin and 0.0250 μg/mL for clavulanic acid in plasma, 0.0500 μg/mL for both analytes in urine. Typical chromatograms of amoxicillin and clavulanic acid at the LLOQ concentration in human plasma and urine are presented in Figs. 2B and 3B .
The intra-batch accuracy for all QC levels of amoxicillin and clavulanic acid is within the range of 91.4 -104.0% in plasma, 88.2 -97.4% in urine, respectively. The inter-batch accuracy is within the range of 92.8 -103.7% in plasma, 91.8 -100.4% in urine, respectively. The intra-batch precision for amoxicillin and clavulanic acid in plasma is less than 7.0%, and less than 9.6% for inter-batch precision. In urine, the intra-batch precision for them is less than 8.4% and the inter-batch precision is less than 9.6% (Table 2) . The values of the recovery rate for amoxicillin and clavulanic acid range from 93.7 -97.2 and 48.5 -53.2% in plasma, 85.1 -90.2 and 51.3 -54.4% in urine at four concentrations, respectively. The recovery of IS1 is 100.6 ± 1.0% in plasma, and recoveries of IS2 and IS3 are 82.7 ± 3.6 and 88.1 ± 4.4% in urine, respectively. The coefficient variation (CV) of both analytes is less than 8.6% (Table 3) .
The relative MF of amoxicillin and clavulanic acid is 102.9 -106.9 and 88.4 -92.0% in plasma, 98.5 -101.9 and 75.4 -77.7% in urine, respectively ( Table 3 ). The relative MF of amoxicillin and clavulanic acid is from 98.3 -102.4 and 87.6 -91.9% in hemolysis, 103.5 -104.8 and 87.0 -93.2% in lipidemia, respectively. There is a slight ion suppression effect on the clavulanic acid signal in urine. The CV% of six sources of urine samples for clavulanic acid is less than 9.0%, which demonstrates that suppression would not affect the quantitation.
No significant carryover is observed following the injection of a high-concentration QC sample in any of the plasma and urine A, Short-term stability; B, post-preparation stability (autosampler, 4 C); C, freeze-thaw cycles; D, long-term (-70 ± 10 C). Recovery (%) = Cafter/Cbefore × 100%; Cbefore, initial concentration; Cafter, measured concentration after treatment under different conditions. methods. After 1/10 and 1/20 dilution, the accuracy and precision of amoxicillin and clavulanic acid are in the range of 100.6 -109.5 and 2.5 -5.4% for plasma samples. For urine samples, the accuracy and precision for dilutions of 1/10, 1/100, 1/1000 and 1/10,000 are in the range of 92.7 -106.3 and 1.3 -11.7%, respectively. The stock solutions of analytes stored at -70 ± 10 C are proved to be stable over 4 months in this study. The results indicate that amoxicillin is stable at room temperature for 6 h, at 4 C in autosampler for 12 h and after three freeze-thaw cycles. Clavulanic acid is stable at room temperature for 4 h, at 4 C in autosampler for 8 h, after two freeze-thaw cycles in human plasma. In human urine, amoxicillin is found to be stable after exposure for 4.5 h at room temperature and 6.5 h at 4 C, 9 h in autosampler at 4 C, and after three freeze-thaw cycles. Clavulanic acid is stable after exposure for 4.5 h at room temperature or 4 C, 7 h in autosampler at 4 C, after two freezethaw cycles in human urine. No degradation of the analytes is found in the long-term stability study at -70 ± 10 C for 61 days in plasma and 26 days in urine ( Table 4 ). The recoveries of amoxicillin and clavulanic acid in whole blood are 95.8 -99.5 and 95.9 -98.2% within 1 h after collection.
Seventy-two plasma samples from three dose groups (12.5% of the total plasma samples), at peak concentration and elimination phase around concentration of LLOQ × 3 were chosen, and 24 urine samples (13.3% of the total urine samples) were performed. The differences of the concentration results between ISR and the initial determination for at least 87.5% (amoxicillin) and 79.2% (clavulanic acid) of plasma samples, 100.0% (amoxicillin) and 79.2% (clavulanic acid) urine samples are within ±20%.
The difference of determined concentrations between our lab and EQA is in the range of -5.6 -2.8%, which indicates that weighing of standard substances and sample preparation procedures are reliable (Table 5) .
Application of the assay in pharmacokinetic analysis
The validated UPLC-MS/MS methods were successfully applied to a pharmacokinetic study following single intravenous infusion of amoxicillin sodium and clavulanate potassium (10:1) in three doses (0.5/0.05, 1.0/0.1 and 2.0/0.2 g) in 12 healthy Chinese subjects. Typical plasma concentration-time curves from a subject for amoxicillin and clavulanic acid are shown in Fig. 4 . The cumulative fractions of three doses recovered in urine over 12 h are determined to be 73.08 ± 9.23, 73.55 ± 12.69 and 65.67 ± 12.82% for amoxicillin, 45.45 ± 7.74, 45.46 ± 10.39 and 36.66 ± 9.47% for clavulanic acid, respectively.
Conclusions
In this study, a rapid, sensitive and reliable method was developed and validated for the simultaneous determination of amoxicillin and clavulanic acid in human plasma. An UPLC-MS/MS method was developed and validated for the simultaneous quantitation of amoxicillin and clavulanic acid in human urine. The two methods were successfully applied to a clinical pharmacokinetic study of amoxicillin sodium and clavulanate potassium (10:1) injection in healthy volunteers. The methods are suitable for the routine analysis of amoxicillin and clavulanic acid in human plasma and urine in pharmacokinetic studies and clinical trials. Fig. 4 Part of pharmacokinetic profiles of amoxicillin (a) and clavulanic acid (b) in plasma in healthy subjects after the intravenous administration of amoxicillin sodium and clavulanate potassium (10:1). EQA, external quality assessment.
